John L. Higgins

2021

In 2021, John L. Higgins earned a total compensation of $9.6M as Chief Executive Officer at Ligand Pharmaceuticals, a 64% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$522,438
Option Awards$2,344,512
Salary$696,583
Stock Awards$6,016,298
Other$7,380
Total$9,587,211

Higgins received $6M in stock awards, accounting for 63% of the total pay in 2021.

Higgins also received $522.4K in non-equity incentive plan, $2.3M in option awards, $696.6K in salary and $7.4K in other compensation.

Rankings

In 2021, John L. Higgins' compensation ranked 1,113th out of 12,415 executives tracked by ExecPay. In other words, Higgins earned more than 91.0% of executives.

ClassificationRankingPercentile
All
1,113
out of 12,415
91st
Division
Manufacturing
384
out of 5,505
93rd
Major group
Chemicals And Allied Products
141
out of 2,375
94th
Industry group
Drugs
118
out of 2,096
94th
Industry
Pharmaceutical Preparations
79
out of 1,546
95th
Source: SEC filing on April 22, 2022.

Higgins' colleagues

We found three more compensation records of executives who worked with John L. Higgins at Ligand Pharmaceuticals in 2021.

2021

Matthew Korenberg

Ligand Pharmaceuticals

Chief Financial Officer

2021

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2021

Charles Berkman

Ligand Pharmaceuticals

General Counsel

News

You may also like